Skip to main content
PlainMeds

What the FDA labels say about taking them together

Aspirin, butalbital, caffeine and codeine and enoxaparin

Aspirin, butalbital, caffeine and codeine's FDA label of May 27, 2026 names enoxaparin in its drug interactions section; enoxaparin's label does not name aspirin, butalbital, caffeine and codeine itself but warns about its class (Barbiturates, Stimulants, NSAIDs (nonsteroidal anti-inflammatory drugs), Opioids (opioid agonists), platelet aggregation inhibitors). The aspirin, butalbital, caffeine and codeine label: “Aspirin may enhance the effects of anticoagulants. Concurrent use may increase the risk of bleeding. Aspirin can also displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time …”

Check it at the source: the aspirin, butalbital, caffeine and codeine FDA label on DailyMed (effective May 27, 2026, Bryant Ranch Prepack); the enoxaparin FDA label on DailyMed (effective May 28, 2026, Sanofi-Aventis U.S. LLC).

What does the aspirin, butalbital, caffeine and codeine label say about enoxaparin?

Aspirin, butalbital, caffeine and codeine label, drug interactions

Clinical Impact: Aspirin may enhance the effects of anticoagulants. Concurrent use may increase the risk of bleeding. Aspirin can also displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Intervention: Evaluate patients for signs of bleeding. Warfarin, heparin, enoxaparin, clopidogrel, prasugrel, rivaroxaban, apixaban Uricosuric Agents

Source: FDA drug label (BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE), ANDA075231 (Lgm Pharma), as published by Bryant Ranch Prepack, effective May 27, 2026 (SPL set 95a33c9b-79a6-47c7-8433-fc217950b88f), via openFDA; the full label on DailyMed

What does the enoxaparin label say about aspirin, butalbital, caffeine and codeine?

Enoxaparin's label does not name aspirin, butalbital, caffeine and codeine itself; it warns about its class (Barbiturates, Stimulants, NSAIDs (nonsteroidal anti-inflammatory drugs), Opioids (opioid agonists), platelet aggregation inhibitors):

Enoxaparin label, warnings and precautions

Use Lovenox with extreme caution in conditions with increased risk of hemorrhage, such as bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.

Enoxaparin label, boxed warning

Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of Lovenox and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment.

Source: FDA drug label (Lovenox), Sanofi-Aventis U.S. LLC, effective May 28, 2026 (SPL set 5017a927-2a24-4f27-89f9-27c805bf7d59), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

4Aspirin, butalbital, caffeine and codeine generic labelers
16Enoxaparin generic labelers
Aspirin, butalbital, caffeine and codeineEnoxaparin
Labeled forPainAngina, Heart attack and coronary artery disease, Blood clots (DVT and PE)
Boxed warningYesYes
Pharmacy cost (NADAC)$1.00 per capsule Ascomp with codeine capsule$6.45 per mL 100 mg/mL syringe
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?